Form 4: Edgewise Therapeutics Chief Development Officer Receives Stock Options and Restricted Stock Units

Robert Blaustein, Chief Development Officer of Edgewise Therapeutics, was granted 160,000 stock options and 30,000 restricted stock units on January 21, 2025.

Summary

• Robert Blaustein, the Chief Development Officer of Edgewise Therapeutics, received stock options and restricted stock units on January 21, 2025.
• He was granted 160,000 stock options with an exercise price of $27.39, which vest over time.
• He also received 30,000 restricted stock units, each representing a contingent right to receive one share of common stock, vesting in four equal annual installments starting January 21, 2026.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the Chief Development Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The vesting of the stock options and restricted stock units is contingent upon the reporting person's continued service with the company.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard practice for executive compensation in the biotech industry, often including a mix of stock options and restricted stock units.
• Vesting schedules are typically structured to incentivize long-term performance and retention, with vesting periods of 3-5 years being common.
• The specific terms of the grant, such as the exercise price and vesting schedule, are often tailored to the individual executive and the company's specific circumstances.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, Edgewise Therapeutics, EWTX, Robert Blaustein